Advances in Radioimmunotherapy in the Age of Molecular Engineering and Pretargeting

REFERENCES

• Pressman D., Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 1953; 6(3)619–623, [CSA]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Burton J., Goldenberg D. M. Radioimmunotherapy of non-Hodgkin's lymphoma: an update. Exp. Rev. Clin. Immunol. 2005; 7(1)47–62, [CSA], [CROSSREF]
   Google Scholar
• Witzig T. E., Gordon L. I., Cabanillas F., Czuczman M. S., Emmanouilides C., Joyce R., Pohlman B. L., Bartlett N. L., Wiseman G. A., Padre N., Grillo-Lopez A. J., Multani P., White C. A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 2002; 20(10)2453–2463, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Davis T. A., Kaminski M. S., Leonard J. P., Hsu F. J., Wilkinson M., Zelenetz A., Wahl R. L., Kroll S., Coleman M., Goris M., Levy R., Knox S. J. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res. 2004; 10(23)7792–7798, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Griffiths G. L., Goldenberg D. M., Jones A. L., Hansen H. J. Radiolabeling of monoclonal antibodies and fragments with technetium and rhenium. Bioconjug Chem. 1992; 3(2)91–99, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zimmer A. M., Spies S. M. New approaches to radiolabeling monoclonal antibodies. Cancer Treat. Res. 1993; 68: 99–109, [CSA]
   PubMedGoogle Scholar
• Anderson C. J., Welch M. J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem. Rev. 1999; 99(9)2219–2234, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Govindan S. V., Griffiths G. L., Stein R., Andrews P., Sharkey R. M., Hansen H. J., Horak I. D., Goldenberg D. M. Clinical-scale radiolabeling of a humanized anticarcinoembryonic antigen monoclonal antibody, hMN-14, with residualizing 131I for use in radioimmunotherapy. J. Nucl Med. 2005; 46(1)153–159, [CSA]
   PubMed Web of Science ®Google Scholar
• Motta-Hennessy C., Sharkey R. M., Goldenberg D. M. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse. J. Nucl. Med. 1990; 37(9)1510–1519, [CSA]
   Google Scholar
• Rogers B. E., Franano F. N., Duncan J. R., Edwards W. B., Anderson C. J., Connett J. M., Welch M. J. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 1995; 55(23 Suppl)5714s–5720s, [CSA]
   PubMed Web of Science ®Google Scholar
• Colcher D., Pavlinkova G., Beresford G., Booth B. J., Choudhury A., Batra S. K. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nucl. Med. 1998; 42(4)225–241, [CSA]
   PubMedGoogle Scholar
• Sharkey R. M., Blumenthal R. D., Hansen H. J., Goldenberg D. M. Biological considerations for radioimmunotherapy. Cancer Res. 1990; 50(3 Suppl)964s–969s, [CSA]
   PubMed Web of Science ®Google Scholar
• Goldenberg D. M., Blumenthal R. D., Sharkey R. M. Biological and clinical perspectives of cancer imaging and therapy with radiolabeled antibodies. Semin. Cancer Biol. 1990; 1(3)217–225, [CSA]
   PubMedGoogle Scholar
• Buchegger F., Pelegrin A., Delaloye B., Bischof-Delaloye A., Mach J. P. Iodine-131-labeled MAb F(ab′)2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice. J. Nucl Med. 1990; 31(6)1035–1044, [CSA]
   PubMed Web of Science ®Google Scholar
• Pedley R. B., Boden J. A., Boden R., Dale R., Begent R. H. Comparative radioimmunotherapy using intact or F(ab′)2 fragments of 131I anti-CEA antibody in a colonic xenograft model. Br. J Cancer. 1993; 68(1)69–73, [CSA]
   PubMed Web of Science ®Google Scholar
• Lane D. M., Eagle K. F., Begent R. H., Hope-Stone L. D., Green A. J., Casey J. L., Keep P. A., Kelly A. M., Ledermann J. A., Glaser M. G. Radioimmunotherapy of metastatic colorectal tumours with iodine-131 -labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br. J Cancer. 1994; 70(3)521–525, [CSA]
   PubMed Web of Science ®Google Scholar
• Behr T. M., Blumenthal R. D., Memtsoudis S., Sharkey R. M., Gratz S., Becker W., Goldenberg D. M. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin. Cancer Res. 2000; 6(12)4900–4907, [CSA]
   PubMed Web of Science ®Google Scholar
• Behr T. M., Memtsoudis S., Sharkey R. M., Blumenthal R. D., Dunn R. M., Gratz S., Wieland E., Nebendahl K., Schmidberger H., Goldenberg D. M., Becker W. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy. Int. J. Cancer. 1998; 77(5)787–795, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Motta-Hennessy C., Pawlyk D., Siegel J. A., Goldenberg D. M. Biodistribution and radiation dose estimates for yttrium- and iodine-labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts. Cancer Res. 1990; 50(8)2330–2336, [CSA]
   PubMed Web of Science ®Google Scholar
• Schott M. E., Schlom J., Siler K., Milenic D. E., Eggensperger D., Colcher D., Cheng R., Kruper W. J., Jr., Fordyce W., Goeckeler W. Biodistribution and preclinical radioimmunotherapy studies using radiolanthanide-labeled immunoconjugates. Cancer. 1994; 73(3 Suppl)993–998, [CSA]
   PubMed Web of Science ®Google Scholar
• Green A., Flynn A., Pedley R. B., Dearling J., Begent R. Nonuniform absorbed dose distribution in the kidney: the influence of organ architecture. Cancer Biother. Radiopharm. 2004; 19(3)371–377, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sgouros G., Squeri S., Ballangrud A. M., Kolbert K. S., Teitcher J. B., Panageas K. S., Finn R. D., Divgi C. R., Larson S M., Zelenetz A D. Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J. Nucl. Med. 2003; 44(2)260–268, [CSA]
   PubMed Web of Science ®Google Scholar
• Koral K. F., Francis I. R., Kroll S., Zasadny K. R., Kaminski M. S., Wahl R. L. Volume reduction versus radiation dose for tumors in previously untreated lymphoma patients who received iodine-131 tositumomab therapy Conjugate views compared with a hybrid method. Cancer. 2002; 94(4 Suppl)1258–1263, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Brenner A., Burton J., Hajjar G., Toder S. P., Alavi A., Matthies A., Tsai D. E., Schuster S. J., Stadtmauer E. A., Czuczman M. S., Lamonica D., Kraeber-Bodere F., Mahe B., Chatal J. F., Rogatko A., Mardirrosian G., Goldenberg D. M. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. J. Nucl. Med. 2003; 44(12)2000–2018, [CSA]
   PubMed Web of Science ®Google Scholar
• Behr T. M., Goldenberg D. M., Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur. J. Nucl. Med. 1998; 25(2)201–212, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Blumenthal R. D., Fand I., Sharkey R. M., Boerman O. C., Kashi R., Goldenberg D. M. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol. Immunother. 1991; 33(6)351–358, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Fand I., Sharkey R. M., Grundy J. P., Goldenberg D. M. Localization by whole-body autoradiography of intact and fragmented radiolabeled antibodies in a metastatic human colonic cancer model. Int. J. Rad. Appl. Instrum. B. 1992; 19(1)87–99, [CSA]
   PubMedGoogle Scholar
• Blumenthal R. D., Sharkey R. M., Haywood L., Natale A. M., Wong G. Y., Siegel J. A., Kennel S. J., Goldenberg D. M. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res. 1992; 52(21)6036–6044, [CSA]
   PubMed Web of Science ®Google Scholar
• Behr T. M., Liersch T., Greiner-Bechert L., Griesinger F., Behe M., Markus P. M., Gratz S., Angerstein C., Brittinger G., Becker H., Goldenberg D. M., Becker W. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002; 94(4 Suppl)1373–1381, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Liersch T., Meller J., Kulle B., Behr T. M., Markus P., Langer C., Ghadimi B. M., Wegener W. A., Kovacs J., Horak I. D., Becker H., Goldenberg D M. Phase-II trial of CEA radioimmunotherapy with 131I-labetuzumab post salvage resection of colorectal metastases in the liver: Five-year safety and efficacy results. J. Clin. Oncol. 2005; 23(27)6763–6770, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Goldenberg D. M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 2005; 46(Suppl 1)115S–127S, [CSA]
   PubMedGoogle Scholar
• Sharkey R. M., Blumenthal R. D., Goldenberg D. M. Anti-antibody enhancement of tumor imaging. Cancer Treat. Res. 1990; 51: 433–455, [CSA]
   PubMedGoogle Scholar
• DeNardo G. L., Maddock S. W., Sgouros G., Scheibe P. O., DeNardo S. J. Immunoadsorption: an enhancement strategy for radioimmunotherapy. J. Nucl. Med. 1993; 34(6)1020–1027, [CSA]
   PubMed Web of Science ®Google Scholar
• Wang Z., Garkavij M., Tennvall J. G., Ohlsson T., Strand S. E., Sjogren H. O. Application of extracorporeal immunoadsorption to reduce circulating blood radioactivity after intraperitoneal administration of indium-111-HMFGl-biotin. Cancer. 2002; 94(4 Suppl)1287–1292, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975; 256(5517)495–497, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kuus-Reichel K., Grauer L. S., Karavodin L. M., Knott C., Krusemeier M., Kay N. E. Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1994; 1(4)365–372, [CSA]
   PubMedGoogle Scholar
• Siegel J. A., Pawlyk D. A., Lee R. E., Sasso N. L., Horowitz J. A., Sharkey R. M., Goldenberg D. M. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50(3 Suppl)1039s–1042s, [CSA]
   PubMed Web of Science ®Google Scholar
• Khazaeli M. B., Conry R. M., LoBuglio A. F. Human immune response to monoclonal antibodies. J. Immunother. 1994; 15(1)42–52, [CSA]
   Web of Science ®Google Scholar
• Qu Z., Griffiths G. L., Wegener W. A., Chang C. H., Govindan S. V., Horak I. D., Hansen H. J., Goldenberg D. M. Development of humanized antibodies as cancer therapeutics. Methods. 2005; 36(1)84–95, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kashmiri S. V., De Pascalis R., Gonzales N. R., Schlom J. SDR grafting-a new approach to antibody humanization. Methods. 2005; 36(1)25–34, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Green L. L Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J. Immunol. Methods. 1999; 231(1–2)11–23, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mueller B M, Reisfeld R A, Gillies S D. Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. Proc. Natl. Acad. Sci. USA. Aug, 1990; 87(15)5702–5, [CSA]
   PubMed Web of Science ®Google Scholar
• Slavin-Chiorini D. C., Koran Hand P., Kashmiri S. V., Calvo B., Zaremba S., Schlom J. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int. J. Cancer. 1993; 53(1)97–103, [CSA]
   PubMed Web of Science ®Google Scholar
• Slavin-Chiorini D. C., Kashmiri S. V., Schlom J., Calvo B., Shu L. M., Schott M. E., Milenic D. E., Snoy P., Carrasquillo J., Anderson K., Horan Hand P. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. 1995; 55(23 Suppl)5957s–5967s, [CSA]
   PubMed Web of Science ®Google Scholar
• Milenic D., Garmestani K., Dadachova E., Chappell L., Albert P., Hill D., Schlom J., Brechbiel M. Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. Cancer Biother. Radiopharm 2004; 19(2)135–147, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Foreno A., Meredith R. F., Khazaeli M. B., Carpenter D. M., Shen S., Thornton J., Schlom J., LoBuglio A. F. A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother. Radiopharm. 2003; 18(5)751–759, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Leung S O, Qu Z, Hansen H J, Shih L B, Wang J, Losman M J, Goldenberg D M, Sharkey R M. The effects of domain deletion, glycosylation, and long IgG3 hinge on the biodistribution and serum stability properties of a humanized IgG1 immunoglobulin, hLL2, and its fragments. Clin. Cancer Res. 1999; 5(10Suppl)3106s–3117s, [CSA]
   PubMedGoogle Scholar
• Pluckthun A. Antibody engineering: advances from the use of Escherichia coli expression systems. Biotechnology (NY). 1991; 9(6)545–551, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Chester K., Pedley B., Tolner B., Violet J., Mayer A., Sharma S., Boxer G., Green A., Nagl S., Begent R. Engineering antibodies for clinical applications in cancer. Tumour Biol. 2004; 25(1–2)91–98, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Russeva M. G., Adams G. P. Radioimmunotherapy with engineered antibodies. Expert. Opin. Biol. Ther. 2004; 4(2)217–231, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Presta L. Antibody engineering for therapeutics. Curr. Opin. Struct. Biol. 2003; 13(4)519–425, [CSA]
   PubMed Web of Science ®Google Scholar
• Wu A. M., Yazaki P. J. Designer genes: recombinant antibody fragments for biological imaging. Q. J. Nucl. Med. 2000; 44(3)268–283, [CSA]
   PubMedGoogle Scholar
• Kortt A. A., Dolezal O., Power B. E., Hudson P. J. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng. 2001; 18(3)95–108, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Souriau C., Hudson P. J. Recombinant antibodies for cancer diagnosis and therapy. Expert. Opin. Biol. Ther. 2003; 3(2)305–318, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hu S., Shively L., Raubitschek A., Sherman M., Williams L. E., Wong J. Y., Shively J. E., Wu A. M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 1996; 56(13)3055–3061, [CSA]
   PubMed Web of Science ®Google Scholar
• Kenanova V., Olafsen T., Crow D. M., Sundaresan G., Subbarayan M., Carter N. H., Ikle D. N., Yazaki P. J., Chatziioannou A. F., Gambhir S. S., Williams L. E., Shively J. E., Colcher D., Raubitschek A. A., Wu A. M. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005; 65(2)622–631, [CSA]
   PubMed Web of Science ®Google Scholar
• Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E. B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature. 1993; 363(6428)446–448, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cortez-Retamozo V., Backmann N., Senter P. D., Wernery U., De Baetselier P., Muyldermans S., Revets H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004; 64(8)2853–2857, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nuttall S. D., Krishnan U. V., Hattarki M., De Gori R., Irving R. A., Hudson P. J. Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol. Immunol. 2001; 38(4)313–326, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yazaki P. J., Wu A. M., Tsai S. W., Williams L. E., Ikler D. N., Wong J. Y., Shively J. E., Raubitschek A. A. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug Chem. 2001; 12(2)220–228, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goel A., Colcher D., Baranowska-Kortylewicz J., Augustine S., Booth B. J., Pavlinkova G., Batra S. K. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 2000; 60(24)6964–6911, [CSA]
   PubMed Web of Science ®Google Scholar
• Goel A., Baranowska-Kortylewicz J., Hinrichs S. H., Wisecarver J., Pavlinkova G., Augustine S., Colcher D., Booth B. J., Batra S. K. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. J. Nucl Med. 2001; 42(10)1519–1527, [CSA]
   PubMed Web of Science ®Google Scholar
• Chauhan S. C., Jain M., Moore E. D., Wittel U. A., Li J., Gwilt P. R., Colcher D., Batra S. K. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur. J. Nucl. Med. Mol Imaging. 2005; 32(3)264–273, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chang C. H., Sharkey R. M., Rossi E. A., Karacay H., McBride W., Hansen H. J., Chatal J. F., Barbet J., Goldenberg D. M. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther. 2002; 1(7)553–563, [CSA]
   PubMed Web of Science ®Google Scholar
• Boerman O. C., van Schaijk F. G., Oyen W. J., Corstens F. H. Pretargeted radioimmunotherapy of cancer: progress step by step. J. Nucl. Med. 2003; 44(3)400–411, [CSA]
   PubMed Web of Science ®Google Scholar
• He J., Liu G., Gupta S., Zhang Y., Rusckowski M., Hnatowich D. J. Amplification targeting: a modified pretargeting approach with potential for signal amplification-proof of a concept. J. Nucl. Med. 2004; 45(6)1087–1095, [CSA]
   PubMed Web of Science ®Google Scholar
• Nakamura K., Fan C., Liu G., Gupta S., He J., Dou S., Kubo A., Rusckowski M., Hnatowich D. J. Evidence of antisense tumor targeting in mice. Bioconjug. Chem. 2004; 15(6)1475–1480, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Reardan D. T., Meares C. F., Goodwin D. A., McTigue M., David G. S., Stone M. R., Leung J. P., Bartholomew R. M., Frincke J. M. Antibodies against metal chelates. Nature. 1985; 316(6025)265–268, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goodwin D. A., Meares C. F., David G. F., McTigue M., McCall M. J., Frincke J. M., Stone M. R., Bartholomew R. M., Leung J. P. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int. J. Rad. Appl. Instrum. B. 1986; 13(4)383–391, [CSA]
   PubMedGoogle Scholar
• Goodwin D. A., Meares C. F., McCall M. J., McTigue M., Chaovapong W. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. J. Nucl. Med. 1988; 29(2)226–234, [CSA]
   PubMed Web of Science ®Google Scholar
• Primus F. J., Macdonald R., Goldenberg D. M., Hansen H. J. Localization of GW-39 human tumors in hamsters by affinity-purified antibody to carcinoembryonic antigen. Cancer Res. 1977; 37(5)1544–1547, [CSA]
   PubMed Web of Science ®Google Scholar
• Stickney D. R., Anderson L. D., Slater J. B., Ahlem C. N., Kirk G. A., Schweighardt S. A., Frincke J. M. Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 1991; 51(24)6650–6655, [CSA]
   PubMed Web of Science ®Google Scholar
• Halpern S. E., Haindl W., Beauregard J., Hagan P., Clutter M., Amox D., Merchant B., Unger M., Mongovi C., Bartholomew R. Scintigraphy with In-111-labeled monoclonal antitumor antibodies: kinetics, biodistribution, and tumor detection. Radiology. 1988; 168(2)529–536, [CSA]
   PubMed Web of Science ®Google Scholar
• Divgi C R., McDermott K., Griffin T. W., Johnson D. K., Schnobrich K. E., Fallone P. S., Scott A. M., Hilton S., Cohen A. M., Larson S. M. Lesion-by-lesion comparison of computerized tomography and indium-111-labeled monoclonal antibody C1 10 radioimmunoscintigraphy in colorectal carcinoma: a multicenter trial. J Nucl Med. 1993; 34(10)1656–1661, [CSA]
   PubMed Web of Science ®Google Scholar
• Podoloff D. A., Part Y. Z., Curley S. A., Kim E. E., Bhadkamkar V. A., Smith R. E. Imaging of colorectal carcinoma with technetium-99m radiolabeled Fab′ fragments. Semin. Nucl. Med. 1993; 23(2)89–98, [CSA]
   PubMed Web of Science ®Google Scholar
• Goldenberg D. M. Perspectives on oncologic imaging with radiolabeled antibodies. Cancer. 1997; 80(12 Suppl)2431–2435, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Le Doussal J. M., Martin M., Gautherot E., Delaage M., Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J. Nucl. Med. 1989; 30(8)1358–1366, [CSA]
   PubMed Web of Science ®Google Scholar
• Le Doussal J. M., Barbet J., Delaage M. Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. Int. J. Cancer Suppl. 1992; 7: 58–62, [CSA]
   PubMedGoogle Scholar
• Karacay H., McBride W. J., Griffiths G. L., Sharkey R. M., Barbet J., Hansen H. J., Goldenberg D. M. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a 99mTc-/188Re-labeled peptide. Bioconjug Chem. 2000; 11(6)842–854, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Janevik-Ivanovska E., Gautherot E., Hillairet de Boisferon M., Cohen M., Milhaud G., Tartar A., Rostene W., Barbet J., Gruaz-Guyon A. Bivalent hapten-bearing peptides designed for iodine-131 pretargeted radioimmunotherapy. Bioconjug. Chem. 1997; 8(4)526–533, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Morel A., Darmon M., Delaage M. Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol. Immunol. 1990; 27(10)995–1000, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., McBride W. J., Karacay H., Chang K., Griffiths G. L., Hansen H. J., Goldenberg D. M. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 2003; 63(2)354–363, 15[CSA]
   PubMed Web of Science ®Google Scholar
• Rossi E. A., Sharkey R. M., McBride W., Karacay H., Zeng L., Hansen H. J., Goldenberg D. M., Chang C. H. Development of new multivalent-bispecific agents for pretargeting tumor localization and therapy. Clin. Cancer Res. 2003; 9(10 Pt 2)3886S–3896S, [CSA]
   PubMed Web of Science ®Google Scholar
• Rossi E. A., Chang C.-H., Losman M. J., Sharkey R. M., Karacay H., McBride W. J., Cardillo T. M., Hansen H. J., Qu Z., Horak I. D., Goldenberg D. M. Pretargeting of CEA-expressing cancer with a trivalent fusion protein produced in myeloma cells. Clin. Cancer. Res. 2005; 11(Suppl 19)7122S–7129S, Pt. 2[CSA]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Cardillo T. M., Rossi E. A., Chang C-H., Karacay K., McBride W. J., Hansen H. J., Horak I. D., Goldenberg D. M. Signal amplification in molecular imaging by pretargeting a multivalent bispecific antibody. Clin Cancer Res. 2005; 11(Suppl 19)7109S–7121S, Pt. 2[CSA]
   PubMedGoogle Scholar
• Sharkey R. M., Karacay H., Cardillo T. M., Chang C.-H., McBride W. J., Rossi E. A., Horak I. D., Goldenberg D. M. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin. Cancer Res. (Suppl.) 2005, (in press)[CSA]
   Google Scholar
• Hnatowich D. J., Virzi F., Rusckowski M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med. 1987; 28(8)1294–1302, [CSA]
   PubMed Web of Science ®Google Scholar
• Kalofonos H. P., Rusckowski M., Siebecker D. A., Sivolapenko G. B., Snook D., Lavender J. P., Epenetos A. A., Hnatowich D. J. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies: preliminary communication. J. Nucl. Med. 1990; 31(11)1791–1796, [CSA]
   PubMed Web of Science ®Google Scholar
• Hnatowich D. J. The in vivo uses of streptavidin and biotin: a short progress report. Nucl. Med. Comm. 1994; 15: 575–577, [CSA]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Karacay H., Griffiths G. L., Behr T. M., Blumenthal R. D., Mattes M. J., Hansen H. J., Goldenberg D. M. Development of a streptavidin-anti-carcinoembryonic antigen antibody, radiolabeled biotin pretargeting method for radioimmunotherapy of colorectal cancer. Studies in a human colon cancer xenograft model. Bioconjug. Chem. 1997; 8(4)595–604, [CSA]
   Google Scholar
• Paganelli G., Pervez S., Siccardi A. G., Rowlinson G., Deleide G., Chiolerio F., Malcovati M., Scassellati G. A., Epenetos A. A. Intraperitoneal radio-localization of tumors pre-targeted by biotinylated monoclonal antibodies. Int. J. Cancer. 1990; 45(6)1184–1189, [CSA]
   PubMed Web of Science ®Google Scholar
• Pimm M. V., Fells H. F., Perkins A. C., Baldwin R. W. Iodine-131 and indium labeled avidin and streptavidin for pre-targetted immunoscintigraphy with biotinylated anti-tumor monoclonal antibody. Nucl. Med. Commun. 1988; 9: 931–941, [CSA]
   PubMed Web of Science ®Google Scholar
• Yao Z., Zhang M., Sakahara H., Saga T., Arano Y., Konishi J. Avidin targeting of intraperitoneal tumor xenografts. J. Natl. Cancer Inst. 1998; 90: 25–29, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rosebrough S. F., Hartley D. F. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. J. Nucl. Med. 1996; 37(8)1380–1384, [CSA]
   PubMed Web of Science ®Google Scholar
• Wilbur D. S., Hamlin D. K., Buhler K. R., Pathare P. M., Vessella R. L., Stayton P. S., To R. Streptavidin in antibody pretargeting. 2. Evaluation Of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjug Chem. 1998; 9(3)322–330, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Yao Z., Zhang M., Sakahara H., Nakamoto Y., Higashi T., Zhao S., Sato N., Arano Y., Konishi J. The relationship of glycosylation and isoelectric point with tumor accumulation of avidin. J. Nucl. Med. 1999; 40(3)479–483, [CSA]
   PubMed Web of Science ®Google Scholar
• Le Doussal J. M., Chetanneau A., Gruaz-Guyon A., Martin M., Gautherot E., Lehur P. A., Chatal J. F., Delaage M., Barbet J. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTP A dimer to primary colorectal tumors: pharmacokinetics, biodistribution, scintigraphy and immune response. J. Nucl. Med. 1993; 34(10)1662–1671, [CSA]
   PubMed Web of Science ®Google Scholar
• Axworthy D. B., Fritzberg A. R., Hylarides M. D., Mallett R. W., Theodore L. J., Gustavson L. M., Su F-M., Beaumier P. L., Reno J. M. Preclinical evaluation of an anti-tumor monoclonal antibody/streptavidin conjugate for pretargeted 90Y radioimmunotherapy in a mouse xenograft model [abstract]. J. Immunother. 1994; 16: 158, [CSA]
   Google Scholar
• Axworthy D. B., Reno J. M., Hylarides M. D., Mallett R. W., Theodore L. J., Gustavson L. M., Su F., Hobson L. J., Beaumier P. L., Fritzberg A. R. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA. 2000; 97(4)1802–1807, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gautherot E., Rouvier E., Daniel L., Loucif E., Bouhou J., Manetti C., Martin M., Le Doussal J. M., Barbet J. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten. J. Nucl Med. 2000; 41(3)480–487, [CSA]
   PubMed Web of Science ®Google Scholar
• Boerman O. C., Kranenborg M. H., Oosterwijk E., Griffiths G. L., McBride W. J., Oyen W. J., de Weijert M., Oosterwijk-Wakka J., Hansen H. J., Corstens F. H. Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. 1999; 59(11)4400–4405, [CSA]
   PubMedGoogle Scholar
• Chiou R. K., Vessella R. L., Elson M. K., dayman R. V., Gonzalez-Campoy J. M., Klicka M. J., Shafer R. B., Lange P. M. Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody. Cancer Res. 1985; 45(12 Pt 1)6140–6146, [CSA]
   PubMed Web of Science ®Google Scholar
• Sands H., Jones P. L., Shah S. A., Palme D., Vessella R. L., Gallagher B. M. Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts. Cancer Res. 1988; 48(1)188–193, [CSA]
   PubMed Web of Science ®Google Scholar
• van Schaijk F. G., Oosterwijk E., Molkenboer-Kuenen J. D., Soede A. C., McBride B. J., Goldenberg D. M., Oyen W. J., Corstens F. H., Boerman O. C. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. J. Nucl. Med. 2005; 46(3)495–501, [CSA]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M. The direct route may not be the best way to home. J. Nucl. Med. 2005; 46(3)391–394, [CSA]
   PubMed Web of Science ®Google Scholar
• Mattes M. J. Biodistribution of antibodies after intraperitoneal or intravenous injection and effect of carbohydrate modifications. J. Natl. Cancer Inst. 1987; 79(4)855–863, [CSA]
   PubMed Web of Science ®Google Scholar
• Schultz J., Lin Y., Sanderson J., Zuo Y., Stone D., Mallett R., Wilbert S., Axworthy D. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. 2000; 60(23)6663–6669, [CSA]
   PubMed Web of Science ®Google Scholar
• Lewis M. R., Zhang J., Jia F., Owen N. K., Cutler C. S., Embree M. F., Schultz J., Theodore L. J., Ketring A. R., Jurisson S. S., Axworthy D. B. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice. Nucl. Med Biol. 2004; 31(2)213–223, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Goshorn S., Sanderson J., Axworthy D., Lin Y., Hylarides M., Schultz J. Preclinical evaluation of a humanized NR-LU-10 antibody-streptavidin fusion protein for pretargeted cancer therapy. Cancer Biother. Radiopharm. 2001; 16(2)109–123, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Forero A., Weiden P. L., Vose J. M., Knox S. J., LoBuglio A. F., Hankins J., Goris M. L., Picozzi V. J., Axworthy D. B., Breitz H. B., Sims R. B., Ghalie R. G., Shen S., Meredith R. F. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 2004; 104(1)227–236, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shen S., Forero A., Lobuglio A. F., Breitz H., Khazaeli M. B., Fisher D. R., Wang W., Meredith R. F. Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. 2005; 46(4)642–651, [CSA]
   PubMed Web of Science ®Google Scholar
• Paganelli G., Magnani P., Zito F., Villa E., Sudati F., Lopalco L., Rossetti C., Malcovati M., Chiolerio F., Seccamani E. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991; 51(21)5960–5966, [CSA]
   PubMed Web of Science ®Google Scholar
• Paganelli G., Grana C., Chinol M., Cremonesi M., De Cicco C., De Braud F., Robertson C., Zurrida S., Casadio C., Zoboli S., Siccardi A. G., Veronesi U. Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. 1999; 26(4)348–357, [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Mirallie E., Sai-Maurel C., Faivre-Chauvet A., Regenet N., Chang C.-H., Goldenberg D. M., Chatal J. F., Barbet J., Thedrez P. Improved pretargeted delivery of radiolabelled hapten to human tumour xenograft in mice by avidin chase of circulating bispecific antibody. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32(8)901–909, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Karacay H., Richel H., McBride W. J., Rossi E. A., Chang K., Yeldell D., Griffiths G. L., Hansen H. J., Goldenberg D. M. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin. Cancer Res. 2003; 9(10)3897S–3913S, Pt 2[CSA]
   PubMed Web of Science ®Google Scholar
• van Schaijk F. G., Boerman O. C., Soede A. C., McBride W. J., Goldenberg D. M., Corstens F. H.M., Oosterwijk E. Comparison of IgG and F(ab′)2-fragments of bispecific anti-RCC x anti-DTIn-1 antibody for pretargeting purposes. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32(9)1089–1095, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Adams G. P., Schier R., McCall A. M., Simmons H. H., Horak E. M., Alpaugh R. K., Marks J. D., Weiner L. M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001; 61(12)4750–4755, [CSA]
   PubMed Web of Science ®Google Scholar
• Fujimori K., Covell D. G., Fletcher J. E., Weinstein J. N. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J. Nucl. Med. 1990; 31(7)1191–1198, [CSA]
   PubMed Web of Science ®Google Scholar
• van Osdol; W W., Sung C., Dedrick R. L., Weinstein J. N. A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J. Nucl. Med. 1993; 34(9)1552–1564, [CSA]
   PubMed Web of Science ®Google Scholar
• Sung C., van Osdol W. W., Saga T., Neumann R. D., Dedrick R. L., Weinstein J. N. Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res. 1994; 54(8)2166–2175, [CSA]
   PubMed Web of Science ®Google Scholar
• Breitz H. B., Weiden P. L., Beaumier P. L., Axworthy D. B., Seiler C., Su P. M., Graves S., Bryan K., Reno J. M. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and 90Y-DOTA-biotin. J. Nucl. Med. 2000; 41(1)131–140, [CSA]
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere P., Faivre-Chauvet A., Ferrer L., Vuillez J. P., Brard P. Y., Rousseau C., Resche I., Devillers A., Laffont S., Bardies M., Chang K., Sharkey R. M., Goldenberg D. M., Chatal J. F., Barbet J. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial. Clin. Cancer Res. 2003; 9(10)3973S–3981S, Pt 2[CSA]
   PubMed Web of Science ®Google Scholar
• Press O. W., Corcoran M., Subbiah K., Hamlin D. K., Wilbur D. S., Johnson T., Theodore L., Yau E., Mallett R., Meyer D. L., Axworthy D. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001; 98(8)2535–2543, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Subbiah K., Hamlin D. K., Pagel J. M., Wilbur D. S., Meyer D. L., Axworthy D. B., Mallett R. W., Theodore L. J., Stayton P. S., Press O. W. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. J. Nucl. Med. 2003; 44(3)437–445, [CSA]
   PubMed Web of Science ®Google Scholar
• Pagel J. M., Hedin N., Subbiah K., Meyer D., Mallet R., Axworthy D., Theodore L. J., Wilbur D. S., Matthews B. C., Press O. W. Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas. Blood. 2003; 101(6)2340–2348, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhang Z., Garmestani K., Schultz J., Axworthy D. B., Goldman C. K., Brechbiel M. W., Carrasquillo J. A., Waldmann T. A. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. USA. 2003; 100(4)1891–1895, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zhang M., Yao Z., Garmestani K., Axworthy D. B., Zhang Z., Mallett R. W., Theodore L. J., Goldman C. K., Brechbiel M. W., Carrasquillo J. A., Waldmann T. A. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002; 100(1)208–216, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Karacay H., Chang C. H., McBride W. J., Horak I. D., Goldenberg D. M. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody. Leukemia. 2005; 19(6)1064–1069, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cheung N. K., Modak S., Lin Y., Quo H., Zanzonico P., Chung J., Zuo Y., Sanderson J., Wilbert S., Theodore L. J., Axworthy D. B., Larson S. M. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. J. Nucl. Med. 2004; 45(5)867–877, [CSA]
   PubMed Web of Science ®Google Scholar
• Yao Z., Zhang M., Axworthy D. B., Wong K. J., Garmestani K., Park L., Park C. W., Mallett R. W., Theodore L. J., Yau E. K., Waldmann T. A., Brechbiel M. W., Paik C. H., Pastan I., Carrasquillo J. A. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and 90Y-labeled 1,4,7,10-tetraazacyclododecane-N,N′,N″,N”′-tetraacetic acid (DOTA)-biotin. Cancer Res. 2002; 62(20)5755–5760, [CSA]
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F., Sai-Maurel C., Campion L., Faivre-Chauvet A., Mirallie E., Cherel M., Supiot S., Barbet J., Chatal J. F., Thedrez P. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol. Cancer Ther. 2002; 1(4)267–274, [CSA]
   PubMed Web of Science ®Google Scholar
• Graves S. S., Dearstyne E., Lin Y., Zuo Y., Sanderson J., Schultz J., Pantalias A., Gray D., Axworthy D., Jones H. M., Auditore-Hargreaves K. Combination therapy with pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin. Cancer Res. Sep., 2003; 9(10)3712–3721, 1Pt 1[CSA]
   PubMed Web of Science ®Google Scholar
• Knox S. J., Goris M. L., Tempero M., Weiden P. L., Centner L., Breitz H., Adams G. P., Axworthy D., Gaffigan S., Bryan K., Fisher D. R., Colcher D., Horak I. D., Weiner L. M. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin. Cancer Res. 2000; 6(2)406–414, [CSA]
   PubMed Web of Science ®Google Scholar
• Breitz H. B., Fisher D. R., Goris M. L., Knox S., Ratliff B., Murtha A. D., Weiden P. L. Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999; 14(5)381–395, [CSA]
   PubMed Web of Science ®Google Scholar
• Vuillez J. P., Kraeber-Bodere F., Moro D., Bardies M., Douillard J. Y., Gautherot E., Rouvier E., Barbet J., Garban F., Moreau P., Chatal J. F. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 di-DTPA hapten: results of a phase I/II trial. Clin. Cancer Res. 1999; 5(10 Suppl)3259s–3267s, [CSA]
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F., Bardet S., Hoefnagel C. A., Vieira M. R., Vuillez J. P., Murat A., Ferreira T. C., Bardies M., Ferrer L., Resche I., Gautherot E., Rouvier E., Barbet J., Chatal J. F. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131I-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin. Cancer Res. 1999; 5(10 Suppl)3190s–3198s, [CSA]
   PubMed Web of Science ®Google Scholar
• Grana C., Chinol M., Robertson C., Mazzetta C., Bartolomei M., De Cicco C., Fiorenza M., Gatti M., Caliceti P., Paganelli G. Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer. 2002; 86(2)207–212, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Kraeber-Bodere F., Faivre-Chauvet A., Sai-Maurel C., Campion L., Fiche M., Gautherot E., Le Boterff J., Barbet J., Chatal J. F., Thedrez P. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131I-labeled F(ab′)2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin. Cancer Res. 1999; 5(10 Suppl)3183s–3189s, [CSA]
   PubMed Web of Science ®Google Scholar
• Tempero M., Leichner P., Baranowska-Kortylewicz J., Harrison K., Augustine S., Schlom J., Anderson J., Wisecarver J., Colcher D. High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial. Clin Cancer Res. 2000; 6(8)3095–3102, [CSA]
   PubMed Web of Science ®Google Scholar
• Valkema R., Pauwels S. A., Kvols L. K., Kwekkeboom D. J., Jamar F., de Jong M., Barone R., Walrand S., Kooij P. P., Bakker W. H., Lasher J., Krenning E. P. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate. Nucl. Med. 2005; 46(Suppl 1)83S–891S, [CSA]
   Google Scholar
• Mirallie E., Vuillez J. P., Bardet S., Frampas E., Dupas B., Ferrer L., Faivre-Chauvet A., Murat A., Charbonnel B., Barbet J., Goldenberg D. M., Chatal J F., Kraeber-Bodere F. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J. Clin. Endocrinol Metab. 2005; 90(2)779–788, [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sharkey R. M., Juweid M., Shevitz J., Behr T., Dunn R., Swayne L. C., Wong G. Y., Blumenthal R. D., Griffiths G. L., Siegel J. A., Leung S.-O., Hansen H. J., Goldenberg D. M. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res. 1995; 55(23 Suppl)5935s–5945s, [CSA]
   PubMed Web of Science ®Google Scholar
• Grana C., Chinol M., Magnani P., Corti A., Sidoli A., Siccardi A. G., Paganelli G. In vivo tumor targeting based on the avidin-biotin system. Tumor Targeting. 1996; 2: 230–239, [CSA]
   Google Scholar
• Weiden P. L., Breitz H. B. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit. Rev. Oncol. Hematol. 2001; 40(1)37–51, [CSA]
   PubMed Web of Science ®Google Scholar